Metraipolis › archive › dc_604dcff00e74

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe — Europe PMC PMID:41578063

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41578063
DOI
10.1093/oncolo/oyag014
License (as archived)
solo-consultazione
Archived
2026-11-06T08:21:19.436Z
SHA-256 of the archived text
2912f18df261e6b4e4f3412c530cfa09ddcad9ed65458f792d763524bce98b01
Stable URL of this page
https://metraipolis.com/documento/dc_604dcff00e74

How to cite

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe — Europe PMC PMID:41578063 — Europe PMC (en), https://europepmc.org/article/MED/41578063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_604dcff00e74 (Metraipolis archive dc_604dcff00e74, sha256 2912f18df261e6b4e4f3412c530cfa09ddcad9ed65458f792d763524bce98b01)
BibTeX
@misc{dc604dcff00e74,
  title = {Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe — Europe PMC PMID:41578063},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41578063},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_604dcff00e74; sha256 2912f18df261e6b4e4f3412c530cfa09ddcad9ed65458f792d763524bce98b01},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41578063. Agents can read the archived copy with the MCP tool read_document.